ReviewChemical & biomedical imaging2024
Recent Progress in Molecular Probes for Imaging of Acute Kidney Injury.
Review in Chemical & biomedical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Detecting drug-induced nephrotoxicity using simultaneous label-free autofluorescence multiharmonic microscopy.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- An HRedox biology · 2026Article
- Construction of an activatable ratiometric fluorescent nanoprobe for HClO detection and imaging in acute kidney injury models.RSC advances · 2026Article
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- HACS omega · 2026Article
- Activatable fluorescent ratiometric probes for early diagnosis and prognostic assessment of acute kidney injury.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI), a prevalent and complex clinical condition associated with elevated risks of morbidity and mortality, necessitates the meticulous detection and monitoring of kidney damage globally. Biomedicine has shown keen interest in molecular probes and detectors for AKI due to their sensitivity, rapidity, and cost-effectiveness. Bioimaging technologies play a significant role in identifying and quantifying AKI indicators, enhancing diagnostic approaches, and potentially refining clinical therapies for immediate injury control. Molecular probes serve as valuable tools for drug screening, uncovering renoprotective components, signaling pathways, and the nephrotoxic effects of drugs. This review comprehensively summarizes the latest advancements in molecular probes, emphasizing their exceptional efficacy in various characteristics, including renal cleanability, multichannel detection capability, near-infrared-II responsiveness, and reactivity toward reactive oxygen species. These probes offer enhanced benefits for assessing kidney damage and evaluating the therapeutic effects of medications while simultaneously reducing toxic effects. Additionally, the review delves into future potentials and challenges in this field, aiming to inspire the development and enhancement of molecular bioimaging for the early diagnosis and treatment of kidney diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.